Back to blog
    Breaking Study Updates

    Retatrutide and Eloralintide at ObesityWeek 2026: The New Data

    16 November 20266 min readBy the Peptx research team

    Retatrutide results in sleep apnoea and knee pain, eloralintide paired with tirzepatide, and the first animal data for a single molecule acting on four receptors. What was announced in November 2026, and what the announcements leave out.

    Three announcements in the first half of November 2026 matter for anyone following the newest metabolic research compounds: new Retatrutide results beyond body weight, more detail on Eloralintide paired with Tirzepatide, and the first animal data for CT-G32, a single molecule acting on four receptors. This post sets out what each source says and what it does not. All three are company announcements made around conference presentations, not peer-reviewed papers.

    Retatrutide: sleep apnoea and knee pain

    ObesityWeek 2026 ran in Washington DC from 14 to 17 November. Ahead of its session on 15 November, the developer of Retatrutide released headline figures from the TRIUMPH phase 3 programme that are not about weight:

    TrialMeasureReported change (up to)
    TRIUMPH-1Sleep apnoea events per hour, 80 weeks36.1 fewer (60.6%)
    TRIUMPH-2 (with type 2 diabetes)Sleep apnoea events per hour, 80 weeks28.4 fewer (48.1%)
    TRIUMPH-1Knee osteoarthritis pain score, 80 weeks4.3 points lower (73.1%)
    TRIUMPH-4Knee osteoarthritis pain score, 68 weeks4.5 points lower (75.8%)

    The release gives the best result in each trial ("up to") and does not give the placebo figures, so these numbers cannot yet be weighed properly. The weight results of TRIUMPH-1 are published: 17.6% to 25.0% at 80 weeks against 3.9% on placebo, in the New England Journal of Medicine. Retatrutide is not approved anywhere as of November 2026. See the Retatrutide profile.

    Eloralintide with Tirzepatide: 23.3% at 48 weeks

    Eloralintide is a selective amylin receptor agonist. Its developer is testing it together with Tirzepatide under the name EloraTZP. The phase 2b results were first reported on 30 September 2026 and were scheduled for an ObesityWeek session on 15 November. The trial enrolled 367 adults with obesity or overweight and type 2 diabetes for 48 weeks.

    • The highest combination arm reported a 23.3% fall in body weight, against 14.8% for Tirzepatide alone and 3.0% on placebo.
    • Eloralintide alone reported 8.2% to 12.3% in the same trial.
    • Gastrointestinal events were more frequent with the combination, and 10.8% to 27.0% of people in the combination arms stopped because of adverse events, against 2.9% on Tirzepatide alone.
    • These figures assume everyone stayed on treatment. The trial has not been published in a journal.

    Two phase 3 trials of a combined product are registered: NCT07881458, which began recruiting in October 2026, and NCT07881432. A poster at the same meeting reported exit interviews from the phase 2 Eloralintide study: 74% of participants said they had fewer food cravings and 52% said they had less food noise. The release does not give the number of people interviewed.

    More on the compound: Eloralintide profile and Eloralintide vs Tirzepatide.

    What about Retatrutide with Eloralintide?

    Neither announcement mentions the two together. As of 16 November 2026 there is no registered trial and no published paper combining Retatrutide with Eloralintide. The pairing is discussed because, between them, the two act on four receptors: GLP-1, GIP and glucagon through Retatrutide, and amylin through Eloralintide. We have set out the evidence either side of that gap in Retatrutide and Eloralintide together: what research shows.

    CT-G32: four receptors in one molecule

    On 4 November 2026, SCOHIA PHARMA and Celltrion presented the first data for CT-G32 (also SCO-940) at TIDES Europe in Amsterdam. It is described as a single molecule acting on the GLP-1, GIP, glucagon and amylin receptors, which is why it is being called a quad agonist.

    • In diet-induced obese rats, the developers reported numerically greater weight loss than Retatrutide at the same molar dose.
    • A smaller share of the weight lost was lean mass, and insulin levels fell.
    • No figures or statistical tests were published. It has not been tested in people.
    • Celltrion aims to apply to start a US trial by February 2027.

    We compare the two in CT-G32 vs Retatrutide, and explain the wider group, including NA-931, in quad agonists explained.

    What to watch next

    • Full ObesityWeek presentations and journal papers for the Retatrutide sleep apnoea and knee results, with placebo figures.
    • Publication of the EloraTZP phase 2b trial, and the phase 3 trials, whose registry completion estimates run to 2029.
    • Whether CT-G32 enters a first study in people in 2027.

    Peptx supplies Retatrutide, Eloralintide and Retalora (Retatrutide 10mg with Eloralintide 2.5mg in one vial) as laboratory research reagents only. See the Retalora blend.

    Sources

    1. Eli Lilly and Company. ObesityWeek 2026 data release, 14 November 2026. PR Newswire
    2. Eli Lilly and Company. EloraTZP phase 2b results release, 30 September 2026. PR Newswire
    3. Jastreboff AM, et al. TRIUMPH-1. N Engl J Med. 2026;395(18):1781-1793. PubMed 42814954
    4. SCOHIA PHARMA. First research results for SCO-940/CT-G32 at TIDES Europe 2026, 4 November 2026. scohia.com

    Browse the Peptx catalogue

    Independently tested compounds, typically 99%+ purity (HPLC), factory-direct pricing. UK stock orders placed by 3pm are posted the same day.

    Sold strictly for laboratory research. Not for human consumption.

    Related research

    What net peptide content meansBrowse the research library